Skip to main content

Table 3 Adverse events (treatment-related)

From: Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

Adverse events SOX+B-mab (n = 22) SOX+C-mab (n = 23)
All grades
(%)
Grade 3
(%)
All grades (%) Grade 3
(%)
Hematologic adverse events
 Leucopenia 3 (13.6) 0 (0.0) 1 (4.3) 0 (0.0)
 Anemia 7 (31.8) 1 (4.8) 6 (26.1) 1 (4.3)
 Thrombocytopenia 6 (27.2) 1 (4.8) 8 (34.8) 3 (13.0)
 Hyperbilirubinemia 8 (36.4) 2 (9.1) 4 (17.4) 0 (0.0)
 Hypoalbuminemia 6 (27.2) 1 (4.8) 7 (30.4) 0 (0.0)
 Aspartate aminotransferase increased 6 (27.2) 0 (0.0) 8 (34.8) 1 (4.3)
 Alanine aminotransferase increased 6 (27.2) 0 (0.0) 9 (39.1) 1 (4.3)
 Hypomagnesemia 1 (4.8) 0 (0.0) 1 (4.3) 0 (0.0)
 Hyperkalemia 1 (4.8) 0 (0.0) 3 (13.0) 0 (0.0)
Nonhematologic adverse events
 Mucositis oral 4 (18.2) 0 (0.0) 6 (26.1) 0 (0.0)
 Nausea 3 (13.6) 0 (0.0) 5 (21.7) 0 (0.0)
 Vomiting 1 (4.8) 0 (0.0) 5 (21.7) 1 (4.3)
 Diarrhea 5 (22.7) 1 (4.8) 11 (43.5) 2 (8.7)
 Anorexia 9 (40.9) 2 (9.1) 9 (39.1) 2 (8.7)
 Fatigue 3 (13.6) 2 (9.1) 5 (21.7) 0 (0.0)
 Malaise 7 (31.8) 1 (4.8) 9 (39.1) 0 (0.0)
 Allergic reaction 0 (0.0) 0 (0.0) 2 (8.7) 0 (0.0)
 Peripheral sensory neuropathy 18 (81.8) 2 (9.1) 16 (69.6) 0 (0.0)
 Peripheral motor neuropathy 3 (13.6) 0 (0.0) 2 (8.7) 0 (0.0)
 Palmar-plantar erythrodysesthesia syndrome 2 (9.1) 0 (0.0) 4 (17.4) 0 (0.0)
 Proteinuria 3 (13.6) 0 (0.0) 3 (13.0) 0 (0.0)
 Hypertension 3 (13.6) 0 (0.0) 2 (8.7) 1 (4.3)
 Skin and subcutaneous tissue disorders 1 (4.8) 0 (0.0) 12 (52.2) 0 (0.0)
 Paronychia 0 (0.0) 0 (0.0) 10 (43.5) 0 (0.0)
Total 20 (90.9) 10 (45.6) 23 (100) 11 (47.8)